Astria Therapeutics Inc

Astria Therapeutics — Investor Presentation (September 2021)

21 slides from Astria Therapeutics's investor presentation, Sep 8, 2021

  1. Slide 1: Corporate Presentation September 2021

    Corporate Presentation September 2021 1 Confidential

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation and various remarks we make during this presentation contain forward-looking statements of Astria Therapeutics, Inc. (“Astria,” the “Company,” “we”, “our” or “us”) within the meaning of applicable securities laws and regulations, including statements with

  3. Slide 3: Introducing Astria Therapeutics

    Our stars illuminate our work, creating an environment of transparency and openness that allows us to build trust with our partners and collaborators. Our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. In

  4. Slide 4: Investment Highlights

    Investment Highlights 4 1. As of 6/30/2021 2. As of market close 9/2/2021 Astria is developing differentiated therapeutics for patients with rare and niche allergic and immunological diseases Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein for the preventative tr

  5. Slide 5: STAR-0215: Our Lead Asset

    STAR-0215: Our Lead Asset 5 OUR LEAD ASSET STAR-0215 (formerly QLS-215): potential to be most patient-friendly preventative treatment option for HAE OUR APPROACH Developing STAR-0215 to be a long-acting monoclonal antibody inhibitor of plasma kallikrein dosed once every 3 months or longer OUR NEAR-T

  6. Slide 6: Hereditary Angioedema: A Rare, Disfiguring, and Potentially Life-Threatening Disease

    • Hereditary angioedema (HAE) is a rare, autosomal dominant genetic disorder1 • HAE is characterized by severe, unpredictable, painful, and sometimes life-threatening edema2: o Skin (hands, feet and face) o Abdomen o Throat/Airway Hereditary Angioedema: A Rare, Disfiguring, and Potentially Life-Thre

  7. Slide 7: Patient Journey

    7 Patient Journey • Patients typically present with symptoms to PCP or ER • Low disease awareness among ER physicians and PCPs, although improving, limits referrals to allergists and HAE specialists for diagnosis • Once diagnosed, most patients are prescribed treatment 1. Images obtained from www.ha

  8. Slide 8: Unmet Need for Effective Preventative Therapy with Lower Treatment Burden

    8 1. Efficacy quoted as reduction in mean attack rate vs placebo; data from respective products’ Prescribing Information. 2. Cortellis, HealthAdvances, EvaluatePharma, and Company research and analysis 3. Company market research with HAE patients. 4. Company market research with HAE prescribers. Unm

  9. Slide 9: Inhibition of Plasma Kallikrein is a Validated Therapeutic Approach for HAE

    Inhibition of Plasma Kallikrein is a Validated Therapeutic Approach for HAE TAKHZYRO .. Current U.S. market leader 2 .. Sales projected to approach $1B in 20213 .. Shire acquired Dyax for $5.9B after Phase 1b with lead program TAKHZYRO4 9 1. TAKHZYRO Prescribing Information, 2018. 2. Takeda. FY2021

  10. Slide 10: HAE Patients and Prescribers are Compelled by Potential for Infrequent Dosing

    HAE Patients and Prescribers are Compelled by the Potential for an Effective Therapy with Infrequent Dosing 10 1. Radojicic C., et al. Poster #63 presented at 2021 AAAAI Virtual Annual Meeting. 2021, Mar. 2. Company research and analysis. 3. Banerji A, et al. Ann Allergy Asthma Immunol. 2020; 124: 6

  11. Slide 11: STAR-0215 Aims to Prevent Attacks in HAE

    STAR-0215 Aims to Prevent Attacks in HAE 11

  12. Slide 12: STAR-0215 Opportunity for Most Patient-Friendly Preventative Treatment Option

    12 1. Narayanan R, et al. J Allergy Clin Immunol. 2020; 45(2): AB105 2. Wang Y, et al. Clin Transl Sci. 2020; 13: 1208-1216 STAR-0215 Opportunity for Most Patient-Friendly Preventative Treatment Option STAR-0215 Goals Potential Benefits Status High potency for plasma kallikrein • Long duration witho

  13. Slide 13: STAR-0215 Shows High Potency Inhibition of Plasma Kallikrein

    STAR-0215 Shows High Potency Inhibition of Plasma Kallikrein • STAR-0215 binding affinity for plasma kallikrein is ~10-fold greater than lanadelumab • STAR-0215 binds a different site on plasma kallikrein than lanadelumab • STAR-0215 is ~10-fold more potent at inhibiting enzymatic activity by 90% th

  14. Slide 14: STAR-0215 Has Shown Substantially Prolonged Plasma Half-Life Compared to Lanadelumab

    STAR-0125 engineered with half-life extension technology • Half-life of mAbs with similar half-life extension technology • Non-human primates: 30 – 40 days • Humans: 70 – 120 days STAR-0215 Has Shown Substantially Prolonged Plasma Half- Life Compared to Lanadelumab in Non-Human Primates 14 1. Data f

  15. Slide 15: Predicted Substantially Longer Duration of Action than Lanadelumab

    The Human in vitro Potency and NHP PK Data for STAR-0215 Predict a Substantially Longer Duration of Action than Lanadelumab • Lanadelumab plasma levels fall below predicted minimum therapeutic concentration (IC90) by approximately day 10 • STAR-0215 remains above predicted minimum therapeutic concen

  16. Slide 16: Preclinical PK/PD Model Predicts Longer Duration of Action for STAR-0215

    Preclinical PK/PD Model Predicts Longer Duration of Action for STAR-0215 Model based on plasma concentrations from cynomolgus PK studies and human plasma kallikrein inhibition determined in in vitro functional assay 16 Lanadelumab STAR-0215 0 20 40 60 80 100 0 50 100 Time (Days) % p K a l i n h i b

  17. Slide 17: Planned STAR-0215 Phase 1 Study Design

    17 • Population: .. Normal Healthy Volunteers (NHVs) • Study Design: .. Single ascending dose in NHV cohorts .. Multiple doses to be explored • Endpoints: .. Safety and tolerability .. Pharmacokinetics – antibody half-life .. Pharmacodynamics – inhibition of plasma kallikrein Planned STAR-0215 Phase

  18. Slide 18: Vision for Astria

    Vision for Astria 18 Value Time 2021 • Continue to advance STAR-0215 to IND – IND-enabling activities – GMP manufacture – Clinical trial design • Present preclinical data 2022 Goals • Complete IND-enabling activities • Submit IND mid-2022 • Establish clinical PoC with initial Phase 1 results by year

  19. Slide 19: STAR-0215 Opportunity

    STAR-0215 Opportunity 19 At Astria, with patients as our guiding stars, our dedicated and passionate team is devoted to bringing life-changing therapies to patients and families impacted by HAE Treatment for rare, genetic disease with established clinical and regulatory path Targeting a clinically v

  20. Slide 20: Astria Well-Positioned for the Future

    • Acquired Quellis Biosciences, Inc. in January 2021 • Concurrent PIPE financing of $110M • PIPE investors included Perceptive Advisors, Fairmount Funds, RA Capital Management, Cormorant Asset Management, Venrock Healthcare Capital Partners, Logos Capital, Boxer Capital, Acorn Bioventures, Commodore

  21. Slide 21: Slide 21

Astria Therapeutics — Investor Presentation (September 2021) on 6ix